Incidence, risk factors of injection site reactions with degarelix investigated
the ONA take:
In a recent study, investigators sought to determine the incidence of injection site reactions (ISRs) after administration of degarelix as well as identify the risk factors for ISRs.
The study involved 50 men receiving subcutaneous therapy for the first time. The men received 240 mg degarelix, administered as two 3-mL subcutaneous injections.
Mean age of patients was 75.6 years, and mean prostate-specific antigen (PSA) level just before degarelix administration was 198.4 ng/mL.
Thirty-three patients received hormonal therapy with degarelix for the first time; 11 patients were receiving an oral steroid (six for prostate cancer, one for hematologic disease, and four for allergic conditions).
Injection site reactions were observed in 25 patients, all categorized as grade 1 or 2. Two patients discontinued digarelix due to ISR. Study findings showed incidence of ISRs in patients receiving subcutaneous therapy for the first time was 64%; incidence of ISRs in patients also receiving an oral steroid was 18%.
The investigators recommend patient education include information on the possibility of ISR due to degarelix prior to administration, especially patients who are not receiving steroids and those who have no experience with subcutaneous injections.
Investigators sought to determine the incidence of injection site reactions after administration of degarelix.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|